Related Experiment Video
Updated: Dec 28, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Follow-up of renal cell carcinoma based on stage and initial treatment]
C Doehn1, M Siebels2, T Steiner3
1Urologikum Lübeck, Am Kaufhof 2, 23566, Lübeck, Deutschland. doehn@urologikum-luebeck.de.
Background:
Renal cell carcinoma is the third most common tumor of the genitourinary system. Small tumors are increasingly treated by nephron-sparing surgery, focal therapy via cryoablation or radiofrequency ablation and also active surveillance. These treatment options are associated with increased follow-up care.
Objectives:
What are the current recommendations on follow-up care for different therapeutic approaches in renal cell carcinoma?
Materials And Methods:
We analyzed different biological aspects regarding renal cell carcinoma, diagnostic procedures as well as recommendations of current guidelines (e.g. German S3, EAU AUA).
Results:
Follow-up of renal cell carcinoma is not well standardized due to the limited amount of data. In general, follow-up should be intensified during the first 3 years following initial therapy as well as in patients with increased risk for tumor recurrence. For risk calculation different prognostic models based on clinical parameters have been published.
Conclusions:
Current recommendations on follow-up care in renal cell carcinoma are based on retrospective studies. Future strategies must include markers and be studied in a prospective manner.
More Related Videos
11:27Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
Related Concept Videos
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury III: Clinical Manifestations